In this work, we propose to target TYRP1 with CAR-T cell therapy as a strategy to decrease the potential on-target off-tumor toxicity through selective action against TYRP1 over-expressing cells and increase the antitumor activity via antigen-binding–mediated primary and secondary T-cell signaling. This evidence concerns the gene TYRP1 and neoplasm.